Table 4.
Comparison of INSTI performance with discrepant results in simulated whole blood and plasma from four HIV-1 seroconverters with other assays during positive and negative time points
| Sample | Days between bleeds | NAT | IA | IA | RT | INSTI | ||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Ag/Ab | IgG/IgM | Ag | Ab | plasma | whole blood | |||
|
| ||||||||
| 924-04 | nonreactive | − | − | − | − | − | + | |
| 924-05 | 16 | reactive | + | − | + | − | − | − |
| 924-06 | 7 | reactive | + | + | + | + | + | + |
| 924-07 | 2 | reactive | + | + | − | + | + | + |
| 924-08 | 5 | reactive | + | + | − | + | + | + |
|
| ||||||||
| 931-05 | reactive | + | − | − | − | − | + | |
| 931-06 | 13 | reactive | + | + | + | + | + | + |
| 931-07 | 5 | reactive | + | + | − | + | + | + |
| 931-08 | 2 | reactive | + | + | − | + | + | + |
| 931-09 | 7 | reactive | + | + | − | + | + | + |
|
| ||||||||
| 940-01 | reactive | + | − | − | − | − | − | |
| 940-02 | 7 | reactive | + | − | + | − | − | + |
| 940-03 | 4 | reactive | + | + | + | + | + | + |
| 940-04 | 4 | reactive | + | + | − | + | + | + |
| 940-05 | 3 | reactive | + | + | − | + | + | + |
|
| ||||||||
| 944-01 | reactive | − | − | − | − | − | − | |
| 944-02 | 2 | reactive | − | − | − | − | − | − |
| 944-03 | 5 | reactive | + | − | + | − | − | + |
| 944-04 | 2 | reactive | + | − | + | − | − | + |
| 944-05 | 5 | nonreactive | + | + | − | + | + | + |
| 944-06 | 2 | reactive | + | + | − | + | + | + |
NAT: FDA-approved diagnostic nucleic acid test; IA Ag/Ab: FDA-approved laboratory-based antigen/antibody immunoassay; IA IgG/IgM: FDA-approved laboratory-based IgG/IgM immunoassay; RT Ag/Ab: FDA-approved antigen/antibody rapid test